Advanced search
Publication Cover
Postgraduate Medicine Volume 106, 1999 - Issue 6
Submit an article Journal homepage
12
Views
12
CrossRef citations to date
0
Altmetric
Original Articles

Update on urine-based markers for bladder cancer

How sensitive and specific are the new noninvasive tests?

Giorgi Pirtskalaishvili Dr Pirtskalaishvili is a resident and Dr Konety is American Foundation of Urologic Diseases Scholar and Ferdinand Valentine Fellow, department of urology, and Dr Getzenberg is associate professor, departments of urology, pathology, and pharmacology, and director of research, Prostate and Urologic Cancer Center, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine.
, MD,
Badrinath R. Konety Dr Pirtskalaishvili is a resident and Dr Konety is American Foundation of Urologic Diseases Scholar and Ferdinand Valentine Fellow, department of urology, and Dr Getzenberg is associate professor, departments of urology, pathology, and pharmacology, and director of research, Prostate and Urologic Cancer Center, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine.Correspondence[email protected]
, MD &
Robert H. Getzenberg Dr Pirtskalaishvili is a resident and Dr Konety is American Foundation of Urologic Diseases Scholar and Ferdinand Valentine Fellow, department of urology, and Dr Getzenberg is associate professor, departments of urology, pathology, and pharmacology, and director of research, Prostate and Urologic Cancer Center, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine.
, PhD
Pages 85-94 | Published online: 30 Jun 2015

References

  • Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA 1999; 49(1): 8–31
  • Shirai T, Fukushima S, Hirose M, et al. Epithelial lesions of the urinary bladder in three hundred and thirteen autopsy cases. Jpn J Cancer Res 1987; 78(10): 1073–80
  • Herr HW. Intravesical BCG: current results, natural history and implications for urothelial cancer prevention. J Cell Biochem (Suppl) 1992; 161: 112–9
  • Pagano F, Bassi P, Gaietti TP, et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991; 145(1): 45–50
  • Prout GR Jr, Barton BA, Griffin PP, et al, for the National Bladder Cancer Group. Treated history of noninvasive grade 1 transitional cell carcinoma. J Urol 1992; 148(5): 1413–9
  • Pode D, Golijanin D, Sherman Y, et al. Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors. J Urol 1998; 159(2): 389–93
  • Landman J, Chang Y, Kavaler E, et al. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998; 52(3): 398–402
  • Berezney R, Coffey DS. Identification of a nuclear protein matrix. Biochem Biophys Res Commun 1974; 60(4): 1410–7
  • Pardoll DM, Vogelstein B, Coffey DS. A fixed site of DNA replication in eucaryotic cells. Cell 1980; 19(2): 527–36
  • Gordon JN, Shu WP, Schlussel RN, et al. Altered extracellular matrices influence cellular processes and nuclear matrix organizations of overlying human bladder urothelial cells. Cancer Res 1993; 53(20): 4971–7
  • Keesee SK, Briggman JV, Thill G, et al. Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr 1996; 6(2&3): 189–214
  • Soloway MS, Briggman JV, Carpinito GA, et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996; 156(2 Pt 1): 363–7
  • Miyanaga N, Akaza H, Ishikawa S, et al. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 1997; 31(2): 163–8
  • Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998; 159(2): 394–8 [Erratum, J Urol 1998; 159(5): 1650]
  • Wiener HG, Mian C, Haitel A, et al. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1998; 159(6): 1876–80
  • Sarosdy MF, de Vere White RW, Soloway MS, et al. Results of a multicenter trial using the BTA test to monitor for and diagnose bladder cancer. J Urol 1995; 154(2 Pt 1): 379–84
  • D'Hallewin MA, Baert L. Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urol 1996; 155(2): 475–6 [Erratum, J Urol 1996, 155(6): 2041]
  • Lanari A, Sternberg CN, Rossetti A, et al. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder. Urology 1997; 49(5): 786–9
  • Van der Poel HG, van Balken MR, Schamhart DH, et al. Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. Urology 1998; 51(1):44–50
  • Getzenberg RH, Konety BR, Oeler TA, et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res 1996; 56(7): 1690–4
  • Sarosdy MF, Hudson MA, Ellis WJ, et al. Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology 1997; 50(3): 349–53
  • Ellis WJ, Blumenstein BA, Ishak LM, et al, for the Multi Center Study Group. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. Urology 1997; 50(6): 882–7
  • Pode D, Shapiro A, Wald M, et al. Noninvasive detection of bladder cancer with the BTA stat test. J Urol 1999, 61(2): 443–6
  • Schmetter BS, Habicht KK, Lamm DL, et al. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997;158(3 Pt 1): 801–5
  • Johnston B, Morales A, Emerson L, et al. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 1997; 158(6):2098–101

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.